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a  b  s  t  r  a  c  t
We  present  a simple  phenomenological  within-host  model  describing  both  the  interaction  between a
pathogen  and  the  immune  system  and  the  waning  of  immunity  after  clearing  of  the  pathogen.  We imple-
ment  the  model  into  a Bayesian  hierarchical  framework  to  estimate  its  parameters  for  pertussis  using
Markov  chain  Monte  Carlo  methods.  We show  that  the  model  captures  some  essential  features  of  the
kinetics  of titers  of  IgG against  pertussis  toxin.  We  identify  a threshold  antibody  level  that  separates  a largeeywords:
aning immunity
ithin-host model
ertussis
erology
increase  in antibody  level  upon  infection  from  a small  increase  and accordingly  might  be interpreted  as  a
threshold  separating  clinical  from  subclinical  infections.  We  contrast  predictions  of the  model  with  obser-
vations  reported  in the  literature  and  based  on  independent  data  and  ﬁnd  a  remarkable  correspondence.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-SA
arameter estimation
ntroduction
Increasingly it has been realized that for many infectious
iseases immunity (whether deriving from vaccination or from
nfection) is not lifelong as the traditional picture suggests. Pertus-
is serves as a prime example, but there are many other infectious
iseases for which waning of immunity has been observed and
ccordingly the success of large scale vaccination programs may
e threatened.
In order to incorporate the effects of temporary immunity in
opulation level (p-level) transmission models that can be used in
 public health context, we need individual level (i-level) models of
he waning of immunity. With the immune system being as com-
lex as it is, it is not an easy task to formulate such i-level models.
oreover, a detailed understanding of the processes underlying
he loss of immunity at the long timescale is as yet missing. Finally,
o be useful as an ingredient in a p-level transmission model, the i-
evel submodel needs to be tractable, preferably by pencil and paper
nalysis (to allow for an analytical formulation of the p-model).
hile a number of modeling studies have investigated the impact
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of waning immunity on the epidemiology of infectious diseases
(Glass and Grenfell, 2003, 2004; Gomes et al., 2004; Reluga et al.,
2008; Alexander et al., 2006; Rouderfer et al., 1994), there are fewer
studies that model the within-host dynamics of the rise and decay
of immunity (Heffernan and Keeling, 2009).
In work in progress (de Graaf et al., in preparation) we develop
a model that aims to describe the p-level heterogeneity in immune
status resulting from the interplay of (re)infection and waning
immunity. Motivated by the tractability issue mentioned above, we
developed a highly stylized submodel for the within-host dynamics
of pathogen concentration and immune response. In order to test
the performance of this submodel in the context of actual i-level
data, we estimated the parameters from time course data of titers
of IgG against pertussis toxin (IgG PT) in serum of 121 patients with
acute respiratory symptoms. Pertussis is a respiratory infection
caused by the pathogen Bordetella pertussis. It is mostly an asymp-
tomatic to mild infection, but can also lead to serious complications
and even death in young children. Therefore, it is included in the
national immunization program of most industrialized countries.
In recent years, a resurge of pertussis incidence among children
has occurred in many countries with high vaccination coverage, the
suspected reasons being a shift of pertussis strains toward ones for
which the current vaccine is less efﬁcacious, and the relatively short
duration of immune protection after vaccination (Mooi et al., 2014;
Jackson and Rohani, 2014). Estimates of seroincidence suggest that
pertussis is circulating in adult populations as well, despite a high
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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accination coverage (Kretzschmar et al., 2010). Such estimates are
ased among others on longitudinal data on rise and decay of IgG
T after a diagnosed infection (Teunis et al., 2002; Versteegh et al.,
005).
Here we present a highly simpliﬁed within-host model describ-
ng both the interaction between pathogen and the immune system
nd the waning of immunity after clearing of the pathogen. Our aim
s not to describe the complexities of an immune response mecha-
istically, but to describe phenomenologically the rise and decline
f antibody levels after infection. We do this in order to interpret
vailable longitudinal serological data and to design a tool that
elps us relate an observed level of antibodies in an individual host
o the probability of observing a symptomatic infection of that host
n a next infection event. We  present the mathematical analysis
f the model. Then we estimate the model parameters from time
ourse data of titers of IgG against pertussis toxin using a Bayesian
ierarchical framework and Markov chain Monte Carlo methods.
he model with the estimated parameters generates predictions
bout observable quantities. In Section ‘Model performance’ we
ontrast these predictions with observations reported in the lit-
rature and based on independent data.
he rise and fall of immunity
The immune status of individuals is often measured in terms
f serum antibody levels, which can then be classiﬁed as posi-
ive or negative relative to a speciﬁed cut-off value. However, one
ould preferably want to judge immune status on the basis of the
ull information available in an antibody titer instead of just using
 dichotomous classiﬁcation. To do this, some understanding of
he time course of antibody levels after infection or vaccination is
ecessary. Sometimes we are in the advantageous situation that
ongitudinal information on the rise and decay of antibody lev-
ls after infection is available. To interpret such data in terms of
nfection events, we need to design a model that describes how
ntibody levels rise as a consequence of boosting events and how
hey decline after the pathogen has been cleared from the host
ndividual.
Denote by b(t) the pathogen concentration (or any measure
or the severity of the (a)symptomatic infection) and by y(t) the
mmune or antibody level at time t. In order to reﬂect time scale
ifferences, we distinguish between two episodes: the infection
pisode and the waning immunity episode.
Infection episode. The infection episode is characterized by
(t) > 0. During this episode the dynamics of b and y are governed
y
db
dt
= 0b − cy (1)
dy
dt
= 1y (2)
ith parameters 0, 1 and c. The parameter 0 describes the
ate at which the pathogen concentration would grow during the
nfection episode if there were no immune response, while the
arameter 1 describes the growth rate of the antibody level during
he infection episode. The parameter c describes the rate at which
ntibodies eliminate pathogen. Arguably the term −cy should be
eplaced by an expression that incorporates a factor b. Closest to
ur approach is André and Gandon (2006). Pugliese and Gandolﬁ
2008) give a short overview (see also references in there, e.g.,
ilchrist-Sasaki and Nowak-May) of within-host models in which
he rate of change of the pathogen concentration incorporates a
otka–Volterra predator-prey term −cby. However, we  choose to
acriﬁce the mechanistic underpinning in order to gain a feature
hat is borne out by observations, viz., that b reaches the level zero
n ﬁnite time. This may  also be achieved by a term −cb˛y withFig. 1. The pathogen concentration b(t) as a function of time t. The graph is drawn
for  the parameter values 0 = 4, 1 = 5, c = 5, b0 = 1 and y0 = 1/25.
0 <  ˛ < 1, but an additional advantage of working with a term −cy is
that we can solve the system (1)–(2) explicitly, which is helpful for
an efﬁcient statistical data analysis.
Waning immunity episode. The waning immunity episode is
characterized by b(t) = 0. The antibody level decreases exponen-
tially with parameter w:
dy
dt
= −wy (3)
In the present paper we  focus on one infection episode and
the subsequent waning immunity episode. In work in progress (de
Graaf et al., in preparation) we  shall incorporate the possibility of
reinfection.
Explicit solution for the infection episode
Let infection take place at time t = 0 with pathogen concentration
b(0) = b0 (we will refer to this initial pathogen concentration at the
start of the infection episode as ‘dose’) and let the initial antibody
level at time t = 0 be y(0) = y0. Assume that the antibody level is
increasing as fast as, or faster than, the pathogen concentration,
i.e., assume that 1 ≥ 0, to guarantee that the infection is cleared.
We now discuss the generic case 1 > 0. The special case 1 = 0
is treated in Appendix A.
The generic case 1 > 0.
The solution of the system of differential equations (1)–(2)
describing the dynamics in the infection episode is given by
b(t) = b0e0t −
cy0
1 − 0
(e1t − e0t)
y(t) = y0e1t
In order to show the qualitative behavior of b, its graph is drawn
for the parameter values 0 = 4, 1 = 5, c = 1/5, b0 = 1 and y0 = 1 in
Fig. 1.
At a certain time t1 the infection is cleared (so t1 is the duration
of the infection episode). Solving b(t1) = 0 for t1 we ﬁnd that
t1 =
1
1 − 0
log
(
1 + (1 − 0)b0
cy0
)
(4)
So the pathogen concentration indeed reaches the zero concentra-
tion in a ﬁnite time.
The peak antibody level y1 at time t1 can then be calculated to
be
y1 := y(t1) = f (y0)where the function f is deﬁned by
f (y0) := y0
(
1 + (1 − 0)b0
cy0
)1/(1−0)
(5)
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Fig. 2. The graphs of f (in blue), bmax (purple), t1 (green) and B (red) for parameter
values 0 = 4, 1 = 5, c = 5 and b0 = 1. The vertical distance of the graph of f to the
45◦ line, the vertical distance of bmax to the horizontal line at level 1, as well as
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yhe  magnitude of t1 and B, are all indicators of the severity of the infection. (For
nterpretation of the references to color in this ﬁgure legend, the reader is referred
o  the web version of this article.)
ote that f maps the initial antibody level y0 to the peak antibody
evel y1 at the end of the infection episode.
The magnitude of f(y0) − y0 gives some indication of the sever-
ty of the infection. Likewise, the length t1 of the time interval
eeded for elimination of the pathogen gives some indication. We
ow introduce two more indicators, bmax and B. At a certain time
max the pathogen concentration b(t) reaches its maximum bmax. If
0/b0 ≥ 0/c we have that tmax = 0 and through that bmax = b(0) = b0.
therwise we have for 1 > 0 that
max = 11 − 0
log
(
0
1
(
1 + (1 − 0)b0
cy0
))
(6)
nd
max := b(tmax) = cy0
0
(
0
1
(
1 + (1 − 0)b0
cy0
))1/(1−0)
(7)
he cumulative amount of pathogen (per unit of volume) during
he entire infection episode is given by
 :=
∫ t1
0
b(t)dt = − b0
0
+ cy0
01
((
1 + (1 − 0)b0
cy0
)1/(1−0)
− 1
)
(8)
In Fig. 2, the graphs of f, bmax, t1 and B, which are all considered as
 function of the initial antibody level y0, are depicted for parameter
alues 0 = 4, 1 = 5, c = 5 and b0 = 1. As we will emphasize in the
ext section, the graphs show that to the left of the minimum of
he function f, the functions bmax, t1 and B increase rapidly with
ecreasing y0.
he function f describing the jump in antibody level
Recall that f maps the initial antibody level y0 to the peak anti-
ody level y1 at the end of the infection episode. The function f is
iven by Eq. (5), which we repeat as
 (y0) = y0
(
1 + (1 − 0)b0
cy0
)1/(1−0)
(9)
ere we list the relevant properties of f, while their derivation is
iven in Appendix A. First, it holds that f(y0) > y0 for all y0, which
akes sense since the antibody level increases during the infec-
ion episode. The function f has a vertical asymptote y0 = 0 and
n oblique asymptote y1 = y0 + (1b0)/c. Solving f′(y0) = 0 we ﬁnd
 unique minimum atmin =
0b0
c
(10)
ecall that bmax = b0 for y0 ≥ (0b0)/c and bmax ≥ b0 for
0 ≤ (0b0)/c. So b decreases for all t ≥ 0 when y0 ≥ ymin whileFig. 3. The graph of the function y1 = f(y0) describing the jump in antibody level from
y0 to y1 for parameter values 0 = 4, 1 = 5, c = 5 and b0 = 1. The two  jumps z1 → v
and z2 → v are reﬂected by the red arrows along the y0-axis.
when y0 < ymin the pathogen ﬁrst increases in concentration before
it decreases and eventually gets cleared.
From the graph of the function f (see Fig. 3), we see that for one
and the same dose b0 two antibody levels at the start of the infec-
tion episode can lead to a particular new antibody level y at the
end of the infection episode; we  expect that this is a robust feature
of a large class of models for pathogen-immune system interac-
tion. Denote these two initial antibody levels by z1 and z2. Based on
Fig. 3 we  interpret a large jump z1 → v as corresponding to a severe
infection and a small jump z2 → v as corresponding to a mild infec-
tion. The mild infection we interpret as an infection that causes no
harm but only boosts the antibody level of the individual, whereas
the severe infection may  also cause disease. It is tempting to iden-
tify ‘mild’ with ‘asymptomatic’ and ‘severe’ with ‘symptomatic’. As
we will see in Section ‘Model performance’, this identiﬁcation does
indeed make sense when we apply the model to pertussis.
Estimation of parameters
In order to interpret longitudinal serological data and imple-
ment the within-host model as a building block of a population
level transmission model, we  need to estimate the parameters 0,
1, c and w as well as the distribution of b0. The distribution of y0
should in principle be determined by the population model itself.
But in order to do the data analysis below we have to estimate
this distribution as well. In this way  serological data can be used
to predict seroresponses (for instance, the (age-dependent) ratio of
symptomatic/severe infections to asymptomatic/mild infections).
In order to estimate the parameters we  slightly modify the book-
keeping by not resetting time when b(t) = 0. This leads to
y(t) =
{
y0e1t if t ≤ t1
y1e−w(t−t1) = y0e1t1−w(t−t1) if t > t1
(11)
This formula can be implemented into a Bayesian hierarchical
framework to estimate parameters using Markov chain Monte
Carlo methods (see Appendix A of Teunis et al. (2012)). Since only
serum antibody titers can be observed, informed prior distribu-
tions must be used for the pathogen related nuisance parameters
b0 and c. Also, the measurement error of antibody titers is assumed
(approximately) known. Time course data of titers of IgG against
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ertussis toxin (IgG PT) in serum of 121 patients were measured by
LISA (FDA method: Giammanco et al., (2003). All patients initially
resented with acute respiratory symptoms and had a laboratory
onﬁrmed pertussis infection. Patients were then followed up for
p to 10 years and sera were taken at irregular intervals, mostly
hen patients returned to the general practitioner with new (not
ecessarily pertussis related) complaints. For details, see Versteegh
t al. (2005).
In order to reduce the number of nuisance parameters from two
viz., b0 and c) to one, we scale the pathogen concentration b in
uch a way that b0 = 1. Recall that during the infection episode the
ynamics of the pathogen concentration b and the antibody level
 are governed by Eqs. (1) and (2). When we deﬁne the scaled
athogen concentration b* by b*(t) : = b(t)/b0, obviously b*(0) = 1.
mplementing the scaling of b into the differential equation (1),
e ﬁnd that
db∗
dt
= 0b∗ −
c
b0
y (12)
his means that effectively we estimate the ratio c/b0, and not any
onger the parameters c and b0 separately. The reduction by one of
he number of parameters that needs to be estimated, adds to the
obustness of the estimates.
The statistical model uses a multivariate normal dis-
ribution as a prior for the vector  = (log(y0), log(1 −
0), log(c/b0), log(1), log(w)) of log transformed model param-
ters with a mean and precision that are in turn distributed
ccording to a normal distribution and a Wishart distribution,
espectively. Note that this formulation implicitly assumes that
1 > 0. The hyperparameters of the distribution of the mean
f  are set to  = (0, − 1, − 2, − 1.9, − 2) and the precision to
 = diag(10, 0.1, 0.1, 0.01, 0.001). The distribution for the hyper-
arameters of the precision is set to W5(A, 10) with A = diag(0.1,
.0, 1.0, 1.0, 10.0). The choice of means for the hyperparameters
s for 1 and w based on estimates in Teunis et al. (2002). The
recisions for the hyperparameters are chosen such that they are
mall, but allow for convergence of the statistical procedure. The
arkov chain Monte Carlo algorithm ﬁts this statistical model to
he set of individual immune responses, thereby generating a set
f parameter estimates for each individual patient. Predictions
an then be obtained by drawing from the multivariate posterior
istribution deﬁned by the estimated hyperparameters. In other
ords, we assume that population heterogeneity is present in all
odel parameters.
The parameter estimates, including T1/2 = (log 2)/w,  which
ives the half-life of antibody decay, are presented in Table 1. Dis-
ributions of the observable immune response characteristics, i.e.,
eak antibody level y1, time t1 to clearance of the pathogen (i.e.,
uration of the infection) and the half-life T1/2, are shown in Fig. 4.
iven the sensitivity of the immune response to the value of y0 for
0 < ymin, we should not be surprised about the wide 95% range for
he compound parameters t1, y1 and T1/2. In Fig. 5 the time course
in days) of the pathogen concentration b and the antibody level y
based on IgG PT titers (in IU/ml)1) are depicted.
odel performanceThe model displays a threshold in the sense that the characteris-
ics of an infection depend heavily on whether the antibody level at
he time of the infection is above or below threshold. If the antibody
1 IU: International Unit, in pharmacology, quantity of a substance, such
s  a vitamin, hormone, or toxin, that produces a speciﬁed effect when
ested according to an internationally accepted biological procedure.
ttp://www.britannica.com/EBchecked/topic/291463/International-Unit-IUmics 9 (2014) 1–7
level exceeds the threshold, infection results in some, but not much,
rise of that level. The magnitude of the rise hardly depends on how
much the original level exceeds the threshold. In contrast, if the
antibody level is below threshold, infection results in a substantial
rise of that level. The magnitude of the rise is very sensitive to how
much the original level is below threshold, so the model predicts
a large variability in sub-threshold immune response. These pre-
dictions are borne out by observations concerning the kinetics of
IgG antibody titers against pertussis toxin as seen in longitudinal
serological data (Versteegh et al., 2005).
In Fig. 4 distributions of the duration t1 of the infection and of the
time scale T1/2 of the waning of immunity are shown. In Richardson
et al. (2001) it is reported that the incubation period of pertussis is
commonly 7 days and that the shedding lasts in 60% of the cases
for more than 14 days and in 20% for more than 42 days. The symp-
tom classiﬁcation of Storsaeter et al. (2003) has more than 21 days
with spasmodic cough as highest category. So the estimates of t1
reported in Table 1 and Fig. 4 seem to have the correct order of
magnitude.
Can we  interpret large and small jumps in antibody levels in
terms of correlates of protection, i.e., assume that above the thresh-
old the antibody level protects the host from clinical or even severe
infection, while below threshold infection results in clinical dis-
ease? For pertussis there has been much uncertainty as to whether
IgG PT levels can be interpreted as correlates of protection (Olin
et al., 2001). However, in Storsaeter et al. (2003) a clear relation-
ship was observed between initial IgG PT levels and occurrence of
symptoms (coughing >14 days). In Fig. 1 of that paper, the nar-
row horizontal band suggests that there is a threshold at around
6.2 IU/ml (95% range: 5.6–6.5 IU/ml) below which symptomatic
infections with pertussis after household exposure were observed
(but note the puzzling fact that the 28–57 days bar in their ﬁgure is
actually above this threshold). This threshold corresponds remark-
ably well with the value 6.4 IU/ml (see Table 1 and Fig. 6) estimated
on the basis of completely different data and the present model.
In Lavine et al. (2011, 2012) the mean duration of pertus-
sis vaccine-induced immunity, interpreted as the period of time
between the moment of vaccination and next infection with per-
tussis, is estimated to be 10.5 years Lavine et al. (2011) and 6–10
years Lavine et al. (2012). Our estimates suggest a half-life of 2 years
(with an upper bound for the 95% range of 7 years). The half-life of
pertussis antibody level is however a different indicator of the time
scale at which pertussis immunity wanes than the mean duration
of (pertussis vaccine-induced) immunity. The latter is in general
longer and also depends on the force of infection. A half-life of 2
years would mean that the peak antibody level at the beginning of
the waning immunity episode is reduced to 3% of that initial level
in 10 years of time. Taking the median as a measure for the center of
the distribution of peak antibody level (note that the mean is not a
good measure in this case, since the distribution is strongly skewed
to the right – see Table 1 and Fig. 4), we observe that a decay to 3%
of that median peak antibody level, i.e., 255.2 IU/ml, would leave
an antibody level of 7.7 IU/ml, which is also perfectly in line with
the estimated threshold value 6.4 IU/ml.
Discussion
Despite its simplicity, the phenomenological within-host model
captures essential features of pathogen-antibody dynamics. In
particular, the model distinguishes between the rising and the
declining phase of the immune response by identifying the time
of clearance (of the pathogen from the host) as a switching point.
As an emergent phenomenon, the model identiﬁes a critical anti-
body level of immune protection against severe diseases (albeit in
the form of a smooth transition rather than a sharp threshold). The
W.F. de Graaf et al. / Epidemics 9 (2014) 1–7 5
Table  1
Estimates of the model parameters and y0 (upper part of the table), and estimates of the observable immune response characteristics and ymin (lower part of the table). It is
assumed that the pathogen concentration b is in 1/ml units.
Variable Interpretation Unit Mean Median 95% range
Model parameters
0 Pathogen growth ratea 1/d 0.1841 0.1382 4.17 × 10−4 − 0.6612
1 Antibody growth rate 1/d 0.2965 0.2276 5.954 × 10−2 − 0.9398
c/b0 Pathogen elimination rate/dose 1/d 2.286 × 10−2 1.646 × 10−2 1.39 × 10−3 − 8.404 × 10−2
w Antibody decay rate 1/d 1.92 × 10−3 1.386 × 10−3 2.576 × 10−4 − 6.767 × 10−3
y0 Initial antibody level IU/ml 0.7369 0.6675 0.3219 − 1.447
Observables
t1 Duration infection d 32.26 26.22 6.748 − 90.5
y1 Peak antibody level IU/ml 1.099 × 103 2.552 × 102 30.2 − 6.371 × 103
T1/2 Half-life antibody decay d 7.237 × 102 5 × 102 1.02 × 102 − 2.69 × 103
ymin Threshold antibody level IU/ml 6.431 8.120 0.164 − 35.377
a In absence of an immune response.
Fig. 4. Estimated distribution of the observable immune response characteristics t1 (time to peak antibody level – in days), y1 (peak antibody level – in IU/ml) and T1/2
(half-life of antibody decay – in days).
Fig. 5. Time course (in days) of the pathogen concentration b and the antibody level y. The median (middle black line) and the 95% range (between the two outer black lines)
are  shown. In the upper two panels the time course of the pathogen concentration (linear scale and log scale) is depicted. The time course of the antibody level (linear scale
and  log scale), and the measured IgG PT titers in serum of 121 patients (in small circles, connected by blue lines), are presented in the lower two panels.
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Fig. 6. Left panel: for pertussis estimated functional relationship between antibody level at the start of the infection and peak antibody level at the moment that the infection
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1 = 0 (see Eq. (14) below).
In the special case 1 = 0 the solution of the system of differ-
ential equations (1)–(2) describing the dynamics in the infections  cleared. The mean (black), median (red) and 95% range are shown. The minimu
.4  IU/ml. Right panel: distribution of the estimated value of ymin at which the min
he  reader is referred to the web  version of this article.)
haracteristics of both sub-threshold and super-threshold infec-
ions correspond well with observed characteristics of pertussis
nfections. Accordingly, the estimation of the model parameters on
he basis of time course data of titers of IgG against pertussis toxin
roduced satisfactory results.
These properties distinguish the present model from models
sed earlier. In Simonsen et al. (2009) a model is used to describe
he pathogen-antibody dynamics that also exhibits a rising and
 declining phase of the immune response. The shapes of those
hases are however more closely linked and therefore the model
s less ﬂexible in accommodating the large difference in time scale
etween the two phases. In Teunis et al. (2012) a model framework
s introduced, in which the rise in antibody titers after infection is
escribed as a discrete jump process, while the decay is exponen-
ial. This simpliﬁcation is ﬂexible enough to be ﬁt to data easily,
ut has the disadvantage that information on the rising phase of
he immune response cannot be used. Both these disadvantages
re overcome by the present model and yet it retains parsimony in
erms of the number of parameters that need to be estimated.
Subsequently, the estimated parameters allow us to predict the
ritical antibody level. A literature search revealed the clinical study
y Storsaeter et al. (2003), and from the completely independent
ata reported there, one can, on the basis of diagnostic informa-
ion, deduce a critical antibody level. The fact that the two  values
re rather close gives us conﬁdence that the within-host model
ntroduced here has potential as a tool for analysing data.
The results presented here will serve as building blocks for
uture work on the effects of immune structure on population level
revalence. In addition, we plan to apply the methodology devel-
ped here to data sets pertaining to other infectious agents.
cknowledgment
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ppendix A. Analysis of the function f (including the
pecial case 1 = 0)In this appendix we derive the results regarding the function f
resented in Section ‘The function f describing the jump in antibody
evel’ and discuss the special case 1 = 0 referred to in Section
Explicit solution for the infection episode’.he function f that separates small and large jumps in antibody level is attained at
 of f is attained. (For interpretation of the references to color in this ﬁgure legend,
In the generic case 1 > 0, we  deﬁne the constants 1 and 2
by
1 =
1
1 − 0
and 2 =
(1 − 0)b0
c
The function f (see Eq. (5)), describing the jump in antibody level
from y0 at the start of the infection to peak antibody level y1 at the
moment that the infection is cleared, we then write in the form
f (y0) = y0
(
1 + 2
y0
)1
(13)
Note that since 1 > 0, we  have that 1 > 1 and 2 > 0. Hence,
f(y0) > y0, which makes sense since the antibody level increases
during the infection episode. The asymptotes of f are given by the
vertical asymptote y0 = 0 (since lim
y0↓0
f (y0) = ∞)  and by the oblique
asymptote y1 = y0 + (1b0)/c (since lim
y0→∞
f (y0)/y0 = 1 and
lim
y0→∞
f (y0) − y0 = lim
y0→∞
y0
(
1 + 12
y0
+ o
(
1/y0
))
− y0
= 12 =
1b0
c
by the binomial series). The derivative of f is given by
f ′(y0) = y−10 (y0 + 2)1−1(y0 + 2 − 12)
Solving f′(y0) = 0, we ﬁnd a unique minimum at ymin = 2(1 − 1),
which corresponds in the original parameters to
ymin =
0b0
c
Deﬁning  = 11−0 , and taking the limit 1 ↓ 0 (so → ∞),  we  ﬁnd
that
lim
1↓0
f (y0) = lim
1↓0
y0
(
1 + (1 − 0)b0
cy0
)1/(1−0)
= lim
→∞
y0
(
1 + 1b0
cy0
1

)
= y0e(1b0)/cy0
which is exactly the function f we ﬁnd in the special case thatepisode is given by
b(t) = (b0 − cy0t)e0t
y(t) = y0e1t
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Then it follows that the function f is given by
 (y0) = y0e
0b0
cy0 (14)
lso in this case it holds that f(y0) > y0, and that the asymptotes of
 are given by y0 = 0 and y1 = y0 + (1b0)/c. Moreover, the minimum
f f is attained at ymin = (0b0)/c.
For the observables t1, tmax, bmax and B we ﬁnd in the special
ase that
t1 = b0cy0
, tmax = max
{
b0
cy0
− 1
0
, 0
}
bmax = max
{
cy0
0
e(0b0/cy0)−1, b0
}
, B = − b0
0
+ cy0
20
(e(0b0)/cy0 − 1)
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